Tonk Erwin H J, van Lindert Anne S R, Verhoeff Joost J C, Suijkerbuijk Karijn P M
Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
Department of Pulmonology University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
Case Rep Oncol. 2019 Aug 6;12(2):621-624. doi: 10.1159/000502202. eCollection 2019 May-Aug.
In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation.
在局部晚期非小细胞肺癌（NSCLC）患者中，度伐利尤单抗（一种抗PD-L1单克隆抗体）巩固治疗已被证明可显著提高放化疗后的无进展生存期和总生存期。在此，我们描述了1例在局部晚期NSCLC患者使用度伐利尤单抗治疗期间发生急性肺炎的病例，该患者至今仍有持续症状并接受类固醇治疗。据我们所知，此前尚未有关于在输注PD-L1抑制剂期间发生急性肺炎的报道。该病例表明，免疫检查点抑制剂（ICI）诱发的肺炎可在治疗期间的任何时候发生，尤其是在放化疗之后。
